BRCA1 and neoplasm: Since this shows synthetic lethality in BRCA1-deficient tumours (Ceccaldi et al. 2015, Mateos-Gomez et al. 2015), this supports further studies to confirm miR-361-3p inhibitor downregulation of POLθ, and whether it can sensitise BC cells to Polθ inhibition in BRCA-proficient vs-deficient tumours.